An interventional study of Blood flood restriction cuff in Anterior Cruciate Ligament Tear, Knee Injuries and Sport Injury, sponsored by Henry Ford Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Henry Ford Health System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.
Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 85th largest by enrollment of the 152 interventional ones that give a count, is one of 14 that started in 2020, is one of 113 with no phase, and was the 89th registered.
627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.
Browse Anterior Cruciate Ligament Injuries studies →44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 13–17
Wake Forest University Health Sciences · Sites in United States
Ages 14–39
University of Michigan · Sites in United States
Ages 14–45
CONMED Corporation · Sites in United States
Ages 14–70
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 9 · Phase 4 16
First in 2001; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 56 across 460 interventional studies indexed under Anterior Cruciate Ligament Injuries.
Median enrollment 50 across the 152 interventional studies, 202 across the 24 observational. Of the 97 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 176 have an industry lead sponsor. The 10 most frequent:
Henry Ford Health System is the lead sponsor of 304 studies on the registry; 51 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 26 (70%) have results posted.
Henry Ford Health System has 4 studies filed under Anterior Cruciate Ligament Injuries — fewer than ten, so there is no comparison to draw.
22 of the studies in Anterior Cruciate Ligament Injuries with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05412381Phase 3Hospital for Special Surgery, New YorkPRP in ACLR to Prevent PTOA | 2026-12-31 |
| NCT06529692University of MichiganMichigan Split-belt Treadmill Training Program to Improve Long-Term Knee Biomechanics After ACL Reconstruction | 2026-12 |
| NCT05488054University Hospitals Cleveland Medical CenterMuscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery | 2026-12 |
| NCT05965310Henry Ford Health SystemAnterior Cruciate Ligament Recovery With Virtual Psychological Intervention | 2027-01 |
| NCT03968913University of California, Los AngelesBiologic Therapy to Prevent Osteoarthritis After ACL Injury | 2027-01-30 |
Add all 22 to your calendar (.ics) → With an account.
Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluating the use of peri-operative blood flow restriction therapy surrounding anterior cruciate ligament tear
The purpose of this study is to examine the effect of utilizing blood flow restriction (BFR) therapy both before and after anterior cruciate ligament reconstruction (ACLR) following a tear. BFR has been proposed to work by restricting arterial inflow leading to an oxygen depleted environment and the ability to induce muscle adaption at lower maximum repetition via reactive hyperemia. Muscle atrophy occurs following ACL tear and reconstruction. Thus, physical therapy is used in the peri-operative period to regain strength with the ultimate goal of returning to activity.
The goal of this investigation is to determine if using BFR during perioperative therapy would lead to increased and expedited strength gains. Additionally we would like to determine if BFR helps patients to pass the standard rehabilitative functional tests and return to play sooner. We will also look at patient reported outcomes metrics and pain scores to determine if BFR has a significant impact on the patient experience surrounding ACL tear and reconstruction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.
Device: Blood flood restriction cuff
The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.
Blood flow restriction cuffs will be used as an augment to physical therapy
Quadriceps Strength in the Operative Leg
Quadriceps strength via handheld dynamometer. Quadriceps torque generation of operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)
Time frame: Change from Initial Clinic Visit to Pre-op
Patient Reported Outcome Measurement Information System
Patient reported outcomes measurement information system score on patient physical function. PROMIS-PF: Assesses Activities of Daily Living and Capabilities. Below 30: Severe limitations, 30-40: Moderate limitations, 40-45: Mild limitations, Above 50: Greater than average physical function. Score scale (0-100) PROMIS-PI: Assesses Pain Indication. Below 55: Within normal limits of pain interference, 50-59: Mild interference, 60-69: Moderate interference, Above 70: Severe pain interference. Score scale (0-100) PROMIS-D: Measures Depressive symptoms: Below 55: Normal to slight symptoms, 55-59: Mild symptoms, 60-69: Moderate symptoms, Above 70: Severe depressive symptoms. Score scale (0-100)
Time frame: Initial Clinic Visit
Participants Reporting Pain Using the Visual Analog Scale
Visual analog scale pain scores, scale 0-10 higher is more pain
Time frame: Three months
Quadricep Strength in Non-operated Leg
Quadriceps torque generation of non-operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)
Time frame: Change from Initial Clinic Visit to Pre-Op
| Milestone | BFR Treatment | Control |
|---|---|---|
| Started | 23 | 22 |
| Completed | 23 | 22 |
| Not completed | 0 | 0 |
Quadriceps strength via handheld dynamometer. Quadriceps torque generation of operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)
| Nm | BFR Treatment | Control |
|---|---|---|
| Initial Clinic Visit | 76.6 ± 41.2 | 84.9 ± 35.8 |
| Pre-Op | -5.7 ± 23.9 | -10.7 ± 27.8 |
Patient reported outcomes measurement information system score on patient physical function. PROMIS-PF: Assesses Activities of Daily Living and Capabilities. Below 30: Severe limitations, 30-40: Moderate limitations, 40-45: Mild limitations, Above 50: Greater than average physical function. Score scale (0-100) PROMIS-PI: Assesses Pain Indication. Below 55: Within normal limits of pain interference, 50-59: Mild interference, 60-69: Moderate interference, Above 70: Severe pain interference. Score scale (0-100) PROMIS-D: Measures Depressive symptoms: Below 55: Normal to slight symptoms, 55-59: Mild symptoms, 60-69: Moderate symptoms, Above 70: Severe depressive symptoms. Score scale (0-100)
| score on a scale | BFR Treatment | Control |
|---|---|---|
| PROMIS-PF | 40.9 ± 6.0 | 41.2 ± 10.4 |
| PROMIS-PI | 59.2 ± 5.6 | 58.8 ± 5.6 |
| PROMIS-D | 44.2 ± 8.2 | 45.4 ± 9.1 |
Visual analog scale pain scores, scale 0-10 higher is more pain
| score on a scale | BFR Treatment | Control |
|---|---|---|
| Participants Reporting Pain Using the Visual Analog Scale | 2.8 ± 2.4 | 1.9 ± 2.0 |
Quadriceps torque generation of non-operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)
| Nm | BFR Treatment | Control |
|---|---|---|
| Initial Clinic Visit | 109.1 ± 57.0 | 115.9 ± 33.5 |
| Pre-Op | -24.5 ± 41.5 | -20.7 ± 41.5 |
Collected over Twelve Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BFR Treatment | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| Control | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Age, Continuous(years) | BFR Treatment | Control | Total |
|---|---|---|---|
| Mean | 26.5 ± 12.0 | 27.0 ± 11.0 | 26.75 ± 12.0 |
| Sex: Female, Male(Participants) | BFR Treatment | Control | Total |
|---|---|---|---|
| Female | 12 | 8 | 20 |
| Male | 11 | 14 | 25 |
| Race and Ethnicity Not Collected(Participants) | BFR Treatment | Control | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | BFR Treatment | Control | Total |
|---|---|---|---|
| United States | 23 | 22 | 45 |
| Laterality of Injury(Participants) | BFR Treatment | Control | Total |
|---|---|---|---|
| Right Leg | 11 | 10 | 21 |
| Left Leg | 12 | 12 | 24 |
| Operative Limb Length(centimenters) | BFR Treatment | Control | Total |
|---|---|---|---|
| Mean | 88.6 ± 7.3 | 90.4 ± 8.3 | 89.5 ± 7.8 |
| Non-Operative Limb Length(centimenters) | BFR Treatment | Control | Total |
|---|---|---|---|
| Mean | 88.6 ± 7.3 | 90.4 ± 8.3 | 89.5 ± 7.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in May 2022, 21 months.
Results were first posted in Nov 2026, 4 years 6 months after primary completion.
Of 279 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's 21 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 14 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anterior Cruciate Ligament Injuries →